SEC Form 4 · accession 0001209191-19-003173
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brandi Roberts
Officer — CFO & SVP, Finance
Period of report
Jan 7, 2019
Accepted (ET)
Jan 9, 2019 · 8:20 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Option to Purchase Common SharesF1 | $1.08 | Jan 7, 2019 | A | 500,000 | A | — | Jan 6, 2029 | Common Shares | 500,000 | 500,000 | D |
Explanation of responses
- F1One quarter of the options shall vest on January 7, 2020 and the balance shall vest in 36 monthly installments thereafter upon the completion of each month of continuous employment.